Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

Abstract Background Cyclin-dependent kinases 2/4/6 (CDK2/4/6) play critical roles in cell cycle progression, and their deregulations are hallmarks of hepatocellular carcinoma (HCC). Methods We used the combination of computational and experimental approaches to discover a CDK2/4/6 triple-inhibitor f...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Ying Zhu, Kun-Bin Ke, Zhong-Kun Xia, Hong-Jian Li, Rong Su, Chao Dong, Feng-Mei Zhou, Lin Wang, Rong Chen, Shi-Guo Wu, Hui Zhao, Peng Gu, Kwong-Sak Leung, Man-Hon Wong, Gang Lu, Jian-Ying Zhang, Bing-Hua Jiang, Jian-Ge Qiu, Xi-Nan Shi, Marie Chia-mi Lin
Format: Artykuł
Język:English
Wydane: BMC 2021-02-01
Seria:Molecular Medicine
Hasła przedmiotowe:
Cyclin-dependent kinases 2/4/6
Hepatocellular carcinoma
Vanoxerine dihydrochloride
Triple inhibitor
Drug combination
Dostęp online:https://doi.org/10.1186/s10020-021-00269-4

Internet

https://doi.org/10.1186/s10020-021-00269-4

Podobne zapisy